HC Wainwright & Co. Reiterates Neutral on Traws Pharma, Maintains $1 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Neutral and maintains $1 price target.
Read original at benzingaStocks · News reference
8-K filing — Traws Pharma, Inc. (TRAW)
Filed: 2026-07-31 AccNo: 0001104659-26-089220 Size: 189 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Jul 31, 2026, 8:15 PM
- Checked
- Jul 31, 2026, 8:15 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Traws Pharma Q2 EPS $(0.16) Beats $(0.34) Estimate
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34) by 51.52 percent. This is a 45.45 percent decrease over losses of $(0.11) per share from the
Read original at benzinga8-K filing — Traws Pharma, Inc. (TRAW)
Filed: 2026-08-14 AccNo: 0001104659-26-097226 Size: 312 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarWHO Director-General Ghebreyesus Says He Considers The Cruise Ship-Linked Hantavirus Outbreak To Be Over
Read original at benzinga